LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $100.20 Consensus Target Price from Brokerages

by · The Markets Daily

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $100.20.

A number of equities analysts recently weighed in on the stock. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Barrington Research restated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, December 15th.

Get Our Latest Stock Report on LMAT

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently made changes to their positions in LMAT. Geneva Capital Management LLC grew its stake in shares of LeMaitre Vascular by 6.0% in the 2nd quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after buying an additional 51,489 shares during the period. First Trust Advisors LP boosted its holdings in LeMaitre Vascular by 35.4% in the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock worth $72,541,000 after acquiring an additional 216,919 shares in the last quarter. Congress Asset Management Co. boosted its holdings in LeMaitre Vascular by 2.7% in the third quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after acquiring an additional 18,298 shares in the last quarter. Geode Capital Management LLC grew its stake in LeMaitre Vascular by 3.0% in the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock valued at $43,174,000 after acquiring an additional 15,036 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of LeMaitre Vascular by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 462,679 shares of the medical instruments supplier’s stock valued at $40,486,000 after acquiring an additional 1,677 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $84.96 on Friday. The stock’s 50-day moving average is $86.24 and its 200-day moving average is $87.28. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $105.55. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The stock has a market cap of $1.93 billion, a P/E ratio of 36.62, a price-to-earnings-growth ratio of 2.10 and a beta of 0.68.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The business had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. During the same period last year, the company earned $0.49 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

See Also